Blog – Page 293

In localized radiorecurrent ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.

Question How do cancer control and perioperative complications compare after salvage focal therapy vs salvage radical prostatectomy for localized radiorecurrent prostate cancer?

Findings In this cohort study with a mean matched cohort size of 554 patients with biopsy-confirmed, localized recurrent prostate cancer, 10-year cancer-specific survival and overall survival were not meaningfully different between salvage focal therapy and salvage radical prostatectomy. The adjusted odds of any and major complications were approximately 24 and 9 times higher, respectively, following salvage radical prostatectomy.

Meaning Salvage focal therapy and salvage radical prostatectomy are both effective for treating localized radiorecurrent prostate cancer, though salvage focal therapy confers fewer perioperative complications.

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in Norway. Men are affected slightly more often than women. Fewer than 5 in 100 patients over the age of 65 survive.

This type of leukemia arises in the bone marrow, where blood cells are produced. The only treatment that can cure the disease is stem cell transplantation, which is highly intensive and therefore not available to everyone, including elderly patients, due to its severe potential side effects.

In a new study, researchers have examined how cancer cells develop in the bone marrow and whether it might be possible to stop them.

Scientists have taken a major step toward treating spinal cord injuries that cause paralysis.

In lab dishes, researchers at Northwestern University grew tiny organoids of the human spinal cord. Then, they injured the samples and administered a treatment that helped the tissue repair and regenerate.

“We decided to develop two different injury models in a human spinal cord organoid and test our therapy to see if the results resembled what we previously saw in the animal model,” biomedical engineer Samuel Stupp says.